Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on July 26, 2021. The company is a Delaware corporation with principal executive offices in Stamford, Connecticut, and its common stock trades on The Nasdaq Stock Market under the symbol "CARA". The report details a material definitive agreement entered into on the date of the report.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Agreements
On July 26, 2021, Cara Therapeutics entered into an API Commercial Supply Agreement with Polypeptide Laboratories S.A. ("PPL"). Key terms include:
- Subject: Manufacture and supply of the active pharmaceutical ingredient (API) CR845/difelikefalin for the company's KORSUVA I.V. product candidate.
- Indication: Treatment of moderate-to-severe pruritus in hemodialysis patients.
- Commitment: Cara is required to purchase its API requirements based on internal forecasts via purchase orders.
- Term: The agreement continues until the fifth anniversary of FDA approval of the new drug application for KORSUVA I.V., with automatic five-year extensions unless terminated by either party.
Outlook, Risks, and Management Commentary
The FDA has conditionally accepted "KORSUVA" as the trade name for difelikefalin injection. Management notes that CR845/difelikefalin remains an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority. The full text of the agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the period ended September 30, 2021.
Investor Verification Checklist
- Verify the status of the New Drug Application (NDA) for KORSUVA I.V. with the FDA.
- Review the full API Commercial Supply Agreement once filed as an exhibit to the Q3 2021 Form 10-Q for specific pricing and volume terms.
- Confirm the company's cash runway and funding status, as this filing does not disclose liquidity metrics.
- Monitor regulatory communications regarding the safety and efficacy evaluation of difelikefalin.